All In Biotech

Drug Trial Radar · NCT05018585

A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes

A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Diamyd® to Preserve Endogenous Beta Cell Function in Adolescents and Adults With Recently Diagnosed Type 1 Diabetes, Carrying the Genetic HLA DR3-DQ2 Haplotype

Last checked: Nov 20, 2026Latest source record: Aug 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. Randomized with 321 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

321

Actual

Start

May 19, 2022

Primary completion

Jun 24, 2026

Study completion Jun 24, 2026

Sponsor

Lead sponsor
Diamyd Medical ABIndustry
Sponsor type
Industry
First posted
Aug 24, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 28 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of DIAGNODE-3 is to evaluate the efficacy and safety of three intranodal injections of 4 μg of Diamyd also known as retogatein compared to placebo, along with oral Vitamin D supplementation, to preserve endogenous beta cell function and influence glycemic parameters in adolescent and adults recently diagnosed with T1D carrying the HLA DR3-DQ2 haplotype.

Conditions

  • Type 1 Diabetes Mellitus

Interventions

  • Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®Biological

    Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®

  • Colecalciferol 2000 IUDietary supplement

    Colecalciferol (vitamin D3) 2000 IU (equivalent to 50 microgram vitamin D3).

  • PlaceboBiological

    Placebo for Diamyd, Alhydrogel® only

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Beta cell functionTime frame: Baseline to 15 months
  2. Glycemic controlTime frame: Baseline to 15 months

Locations

60 sites in 9 countries. Site status is shown where the registry gives one.

  • Mary and Dick Allen Diabetes Center at Hoag Hospital

    Newport Beach, California

  • Stanford University School of Medicine Center for Academic Medicine

    Palo Alto, California

  • UCSD/ Rady Children's Hospital

    San Diego, California

  • University of Colorado Anschutz Medical Campus, Barbara Davis Center for Childhood Diabetes

    Aurora, Colorado

  • Diabetes Research Institute (DRI)-University of Miami Leonard M. Miller School of Medicine (UMMSM)

    Miami, Florida

  • Rocky Mountain Diabetes and Osteoporosis Center

    Idaho Falls, Idaho

  • University of Iowa Hospital and Clinics

    Iowa City, Iowa

  • Johns Hopkins University

    Baltimore, Maryland

  • The Joslin Center

    Boston, Massachusetts

  • Washington University Diabetes Center at Barnes Jewish Hospital

    St Louis, Missouri

  • Hassenfeld Children's Hospital at NYU Langone Health, Pediatric Diabetes Center

    New York, New York

  • Amarillo Medical Specialists

    Amarillo, Texas

  • Diabetes & Glandular Disease Clinic

    San Antonio, Texas

  • Nemocnice Jihlava, příspěvková organizace

    Jihlava, Czechia

  • Institut klinické a experimentální medicíny

    Prague, Czechia

  • Fakultní nemocnice v Motole

    Prague, Czechia

  • Krajská zdravotní, a.s. - Masarykova nemocnice v Ústí nad Labem, o.z.

    Ústí nad Labem, Czechia

  • Liina Viitas OÜ

    Pärnu, Estonia

  • North-Estonian Regional Hospital

    Tallinn, Estonia

  • Tartu University Hospital

    Tartu, Estonia

  • Tartu University Hospital, Children's Clinic

    Tartu, Estonia

  • Diabetespraxis Dr. Braun

    Berlin, Germany

  • Diabetologische Schwerpunktpraxis Dres. Klaus

    Dortmund, Germany

  • DZDM - Diabeteszentrum Duisburg Mitte

    Duisburg, Germany

  • Justus-Liebig-Universität Gießen

    Giessen, Germany

  • Óbudai Egészségügyi Centrum

    Budapest, Hungary

  • Heim Pál Országos Gyermekgyógyászati Intézet, Diabetológia

    Budapest, Hungary

  • Észak-Budai Szent János Centrumkórház, Kútvölgyi Kórház, Belgyógyászat

    Budapest, Hungary

  • Szabolcs-Szatmár-Bereg Megyei Kórházak és Egyetemi, Oktatókórház, Jósa András Oktatókórház, Gyermekosztály

    Nyíregyháza, Hungary

  • Markusovszky Egyetemi Oktatókórház, Diabetológiai Szakrendelés

    Szombathely, Hungary

  • CTU Vasculaire Geneeskunde, Locatie Academic Medical Center (AMC)

    Amsterdam, Netherlands

  • Albert Schweitzer Ziekenhuis

    Dordrecht, Netherlands

  • Bethesda Diabetes Research Center te Hoogeveen

    Hoogeveen, Netherlands

  • Dept. of Nephrology / Dept. of Endocrinology, Leiden University Medical Center (LUMC)

    Leiden, Netherlands

  • Vivendia

    Nijmegen, Netherlands

  • Diabeter Nederland te Rotterdam

    Rotterdam, Netherlands

  • Uniwersytecki Dziecięcy Szpital Kliniczny im. L. Zamenhofa w Białymstoku, Klinika Pediatrii, Endokrynologii, Diabetologii z Pododdziałem Kardiologii

    Bialystok, Poland

  • Uniwersyteckie Centrum Kliniczne, Klinika Pediatrii, Diabetologii i Endokrynologii

    Gdansk, Poland

  • SP ZOZ Szpital Uniwersytecki w Krakowie, Oddział Kliniczny Chorób Metabolicznych i Diabetologii

    Krakow, Poland

  • NZOZ Przychodnia Specjalistyczna Medica

    Lublin, Poland

Showing 40 of 60 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.